Literature DB >> 509853

Haemoperfusion in the management of digoxin toxicity: is it warranted?

J T Slattery, J R Koup.   

Abstract

Several recent publications have encouraged the use of hemoperfusion to remove digoxin from the body of overdosed patients. The usefulness of haemoperfusion in removing digoxin from the body has therefore been examined using pharmacokinetic simulation techniques and published data. Haemoperfusion for a period of 4 hours with a clearance of 100 ml/min removes less than 7% of the amount of digoxin in the body (including that in the gastrointestinal tract at the beginning of haemoperfusion), regardless of the time after the dose that haemoperfusion is started. Dramatic therapeutic benefit in digoxin intoxication is unlikely to be a consequence of the amount of digoxin removed from the body by haemoperfusion. If therapeutic benefit is derived from a transient decline of digoxin concentration in plasma, it may be expected to be negated as the drug redistributes from tissues.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 509853     DOI: 10.2165/00003088-197904050-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  12 in total

1.  Treatment of digitalis intoxication by charcoal hemoperfusion (CHP).

Authors:  A Carvallo; B Ramirez; H Honig; J Knepshield; G E Schreiner; M C Gelfand
Journal:  Trans Am Soc Artif Intern Organs       Date:  1976

2.  Hemoperfusion in digitalis intoxication: a comparative study of coated versus uncoated charcoal.

Authors:  M Tobin; F Cerra; J Steinbach; B Mookerjee
Journal:  Trans Am Soc Artif Intern Organs       Date:  1977

3.  Bioavailability of digoxin from tablets. II. Radioimmunoassay and disposition pharmacokinetics of digoxin after intravenous administration.

Authors:  L Nyberg; K E Andersson; A Bertler
Journal:  Acta Pharm Suec       Date:  1974-11

4.  Role of pharmacokinetics in drug dosage adjustment. I. Pharmacologic effect kinetics and apparent volume of distribution of digoxin.

Authors:  R H Reuning; R A Sams; R E Notari
Journal:  J Clin Pharmacol New Drugs       Date:  1973-04

5.  Hemoperfusion in drug overdose.

Authors:  M C Gelfand
Journal:  JAMA       Date:  1978-12-15       Impact factor: 56.272

6.  Resin hemoperfusion in acute digoxin intoxication.

Authors:  G H Gleeson; J R Nicotero; F C Duffy; F B Kennedy; A R Ticzon
Journal:  JAMA       Date:  1978-12-15       Impact factor: 56.272

7.  Treatment of severe drug overdosage with charcoal hemoperfusion.

Authors:  M C Gelfand; J F Winchester; J H Knepshield; K M Hanson; S L Cohan; B S Strauch; K L Geoly; A C Kennedy; G E Schreiner
Journal:  Trans Am Soc Artif Intern Organs       Date:  1977

Review 8.  Clinical pharmacokinetics of digoxin.

Authors:  E Iisalo
Journal:  Clin Pharmacokinet       Date:  1977 Jan-Feb       Impact factor: 6.447

9.  Hemoperfusion removal of digoxin from dogs.

Authors:  T P Gibson; S V Lucas; H A Nelson; A J Atkinson; G T Okita; P Ivanovich
Journal:  J Lab Clin Med       Date:  1978-04

10.  Advanced digoxin toxicity in renal failure: treatment with charcoal hemoperfusion.

Authors:  T Marbury; J Mahoney; L Juncos; R Conti; R Cade
Journal:  South Med J       Date:  1979-03       Impact factor: 0.954

View more
  1 in total

Review 1.  Diagnosis and treatment of digoxin toxicity.

Authors:  G Y Lip; M J Metcalfe; F G Dunn
Journal:  Postgrad Med J       Date:  1993-05       Impact factor: 2.401

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.